Athersys Inc (ATHX)

1.18
0.04 3.50
NASDAQ : Health Care
Prev Close 1.14
Open 1.12
Day Low/High 1.12 / 1.18
52 Wk Low/High 0.94 / 2.90
Volume 620.37K
Avg Volume 791.70K
Exchange NASDAQ
Shares Outstanding 109.80M
Market Cap 124.08M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Overview Of MultiStem® Clinical Trial In Japan Presentation At International Stroke Conference 2017

Overview Of MultiStem® Clinical Trial In Japan Presentation At International Stroke Conference 2017

Details of Healios' Phase II/III trial (HLCM051) being presented by stroke expert and lead investigator Dr. Kyohiro Houkin

Athersys Reports Third Quarter 2016 Results

Athersys Reports Third Quarter 2016 Results

Management to host conference call at 4:30 pm EST today

Athersys Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Study Of MultiStem® Treatment For Ischemic Stroke

Athersys Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Study Of MultiStem® Treatment For Ischemic Stroke

SPA for pivotal registration trial clarifies and de-risks development pathway for stem cell therapy

Athersys Announces Acceptance By PMDA Of Clinical Trial Notification In Japan For Treatment Of Ischemic Stroke With MultiStem®

Athersys Announces Acceptance By PMDA Of Clinical Trial Notification In Japan For Treatment Of Ischemic Stroke With MultiStem®

Study designed to provide confirmatory evidence of safety and effectiveness under Japan's accelerated regulatory pathway for qualified regenerative medicine therapies

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARRS, ATAX, CYRN, DAR, GTIM, MLP, NPTN, RCMT, RDN, SEB, SNE, TISA Downgrades: APEI, ATHX, CFBK, HMHC Initiations: CHCT Read on to get TheStreet Quant Ratings' detailed report:

Athersys Reports Second Quarter 2016 Results

Athersys Reports Second Quarter 2016 Results

Management to host conference call at 4:30pm EDT today

Athersys Joins Russell 3000® Index

Athersys Joins Russell 3000® Index

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATHX, BMY, HDSN, NX, OEC, PMT Downgrades: ALSK, CENX, CLI, EVR, MLP, PII, UFPT Initiations: BPMC, EVA Read on to get TheStreet Quant Ratings' detailed report:

Athersys Reports First Quarter 2016 Results

Athersys Reports First Quarter 2016 Results

Management to host conference call at 4:30pm EDT today

Athersys (ATHX) Strong On High Relative Volume Today

Athersys (ATHX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Athersys (ATHX) as a strong on high relative volume candidate

Athersys Reports Fourth Quarter And 2015 Annual Results

Athersys Reports Fourth Quarter And 2015 Annual Results

Management to Host Conference Call at 4:30pm EST Today

Should You Buy Into Athersys’ Latest Spin on Failed Stroke Therapy?

Should You Buy Into Athersys’ Latest Spin on Failed Stroke Therapy?

About that 17% bump in Athersys' stock price Thursday: Don't be a sucker.

Here’s Why Athersys (ATHX) Stock is Jumping Today

Here’s Why Athersys (ATHX) Stock is Jumping Today

Athersys (ATHX) stock is up after the company announced positive results from the analysis of one year follow-up data from a Phase 2 study of its therapy for ischemic strokes.

One-Year Results From Phase 2 Stroke Study Of MultiStem® Cell Therapy Demonstrate A Significantly Higher Rate Of Complete Or Nearly Full Recovery

One-Year Results From Phase 2 Stroke Study Of MultiStem® Cell Therapy Demonstrate A Significantly Higher Rate Of Complete Or Nearly Full Recovery

Data Presented at 2016 International Stroke Conference Demonstrate Statistically Significant Improvement in Excellent Outcomes When Evaluating All Subjects and Key Subgroups

Athersys' MultiStem® Data To Be Presented At International Stroke Conference 2016

Athersys' MultiStem® Data To Be Presented At International Stroke Conference 2016

Multiple Presentations by Leading Stroke Clinical Investigators

Athersys And Healios Announce R&D Day

Athersys And Healios Announce R&D Day

Special Event to be Held Thursday, February 4, 2016, at the Harvard Club of New York City